Biotech & Pharma

Syngene Expands Integrated Drug Development and Manufacturing Services with BMS

31 sec read0 views0 listens

Syngene International has extended its strategic collaboration with Bristol Myers Squibb through 2035, significantly broadening the scope of services to encompass the entire drug development lifecycle. This agreement is notable for Biotech/Pharma investors because it signals continued reliance on contract development and manufacturing organizations, particularly for companies seeking to streamline operations and accelerate timelines. Investors should monitor the development of new capabilities and infrastructure planned over the next decade as a result of this long-term partnership.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & Pharma20 hours ago32 sec read

SARS-CoV-2 Protein Fuels Lung Inflammation by Hijacking Macrophages

Researchers have identified the SARS-CoV-2 protein ORF8 as a key driver of lung inflammation in severe COVID-19 cases, demonstrating it reprograms macrophages to enhance viral infection. This finding is significant for the biotech and pharma sectors ...

Ali Nemati

Cybersecurity1 day ago30 sec read

Blood biomarker offers window into Alzheimer's drug response

Researchers have identified changes in a blood-based biomarker, phosphorylated tau 217 (p-tau217), as a potential indicator of patient response to lecanemab, a treatment for early Alzheimer’s disease. This development is significant for cybersecurity...

Ali Nemati

Cybersecurity2 days ago36 sec read

Q&A: Advancing cancer biotech therapies with a multipronged approach

BriaCell Therapeutics is developing "off-the-shelf" cellular immunotherapies designed to activate a patient’s immune system to fight cancer, a significant departure from personalized cell therapies that face cost and scaling limitations. Their lead c...

Ali Nemati